Here's Why Sichuan Kelun Pharmaceutical (SZSE:002422) Has Caught The Eye Of Investors

Simply Wall StDec 10 19:10 ET

Sichuan Kelun Pharmaceutical Gets China Clinical Trial Nod for Anti-Tumor Drug

MT NewswiresDec 5 05:10 ET

Express News | Sichuan Kelun Pharmaceutica Says Five Company Products Include in China Drug Catalog

ReutersNov 28 22:59 ET

Sichuan Kelun Pharmaceutical (002422.SZ) pharmaceuticals included in the national medical insurance catalog.

sichuan kelun pharmaceutical (002422.SZ) announced that on November 28, 2024, the National Medical Insurance Administration and the Ministry of Human Resources...

Zhitong FinanceNov 28 22:54 ET

Sichuan Kelun Pharmaceutical (002422.SZ): The core product Lukan Sanduo Monoclonal Antibody (sac-TMT) of its subsidiary, based on the OptiTROP-Breast01 study, has been approved by the National Drug Administration for the treatment of second-line and above

On November 27, Kelun Pharmaceutical announced that Sichuan Kelun Pharmaceutical Co., Ltd. (referred to as the "Company") recently learned that its controlling subsidiary Sichuan Kelun Botai Biomedical Co., Ltd. (referred to as "Kelun Botai") released the first domestically produced antibody-drug conjugate (ADC) Lushan Shatu Pertuzumab targeting the human zygote nourishing cell surface antigen 2 (TROP2) for adult patients with unresectable local advanced or metastatic triple-negative breast cancer (TNBC) who have received at least two prior systemic treatments (with at least one treatment targeting the advanced or metastatic stage).

Gelonghui FinanceNov 26 22:50 ET

While Institutions Invested in Sichuan Kelun Pharmaceutical Co., Ltd. (SZSE:002422) Benefited From Last Week's 3.3% Gain, Retail Investors Stood to Gain the Most

Simply Wall StNov 21 19:02 ET